Skip to main content

Table 3 HRQOL results in MG subgroups

From: An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts

 

SNMG (n = 115)

AChR MG (n = 626)

MuSK MG (n = 41)a

Thymoma-MG (n = 70)

Adjusted p-value

Female [n, %]

63 (41.4)

376 (41.3)

27 (55.1)

37 (52.9)

NS

Age at study entry [yrs, SD]

54.2 (17)

61.7 (18)

52.2 (15)

61.5 (14)

*b

Mean age at onset [yrs, SD]

39.5 (18)

47.1 (22) c

40.5 (17)

47.0 (17)c

NS

Mean age at diagnosis [yrs, SD]

41.8 (18)

48.7 (21) c

43.1 (16)

50.4 (14.3)c

NS

Disease duration [yrs, SD]

13.5 (13)

13.4 (13)

11.8 (10)

10.2 (7.9)

NS

Disease course [n, %]

     

Remission

24 (20.9)

151 (24.1)

11 (26.2)

16 (22.9)

NS

Ocular

20 (17.4)

76 (12.1)

1 (2.4)

5 (7.1)

*d

Bulbar

14 (12.2)

61 (9.7)

8 (19)

12 (17.1)

*d

Generalized

57 (49.6)

338 (54)

22 (52.4)

37 (52.9)

NS

Current treatment [n, %]

     

Pyridostigmine

41 (35.7)

227 (36.3)

4 (9.5)

55 (78.6)

*e

Prednisolone

25 (21.7)

205 (32.7)

21 (50)

35 (50)

*f

Immunosuppressives

23 (20.2)

165 (26.6)

27 (65.7)

35 (50)

*f

Combined

37 (32.5)

274 (44.1)

34 (82.9)

46 (65.7)

*g

SF- 36 [mean, SD]

     

Physical functioning

71.3 (26.3)

62.9 (30.3)

69.3 (26.7)

65.4 (27.6)

NS

Role Physical

53.8 (41.7)

51.1 (44.3)

49.4 (45.9)

55.6 (42.6)

NS

Bodily pain

68.9 (28.2)

69.7 (28.1)

73.3 (24.7)

68.4 (26.3)

NS

General health

52.8 (16.9)

52.6 (15.4)

51.2 (14.3)

51.4 (13.8)

NS

Vitality

48.9 (21.1)

52.2 (23.2)

54.8 (20.5)

52.0 (21.2)

NS

Social functioning

74.3 (26.5)

72.5 (26.9)

71.9 (27.3)

72.1 (27.6)

NS

Role Emotional

79.2 (35.6)

75.4 (38.8)

82.1 (35.0)

76.2 (39.0)

NS

Mental Health

74.5 (17.8)

75.6 (17.9)

69.3 (19.7)

73.7 (20.0)

NS

PCS

61.7 (22.5)

59.1 (23.9)

60.8 (22.6)

60.0 (22.2)

NS

MCS

69.2 (18.8)

69.0 (21.5)

69.5 (20.5)

68.5 (21.7)

NS

Norm-based PCS

43.6 (11.1)

42.1 (11.1)

43.7 (10.1)

42.6 (10.2)

NS

Norm-based MCS

50.2 (9.1)

50.7 (9.3)

49.2 (9.1)

49.9 (10.1)

NS

  1. Adjusted p-value is calculated with age, sex, country and antibodies as dependent variables with logistic regression analysis
  2. Footnote aMuSk MG sample includes two MuSK MG patients from Norway, 19 MuSk patients from the study area North- and south Holland and in addition 21 from the rest of the Netherlands
  3. *bSNMG and MuSK MG were younger than AChR MG and Thymoma MG
  4. *cAChR MG and Thymoma MG patients were older than SNMG at onset and diagnosis
  5. *dThere were more ocular among the SNMG and more bulbar among thymoma MG and MuSK MG
  6. *eMuSK MG patients used less pyridostigmine than AChR MG patients (p = 0.032)
  7. *fMuSK MG patients used more prednisolone than AChR MG (p = 0.030) and SNMG (p = 0.017) and more secondary immunosuppressives than AChR MG (p = 0.006) and SNMG (p = 0.007)
  8. *gBoth MuSK MG and Thymoma MG used more combination therapy with secondary immunosuppressive drugs and prednisolone than SNMG and AChR MG
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us